The Pose study - panic control treatment versus panic-focused psychodynamic psychotherapy under randomized and self-selection conditions:study protocol for a randomized controlled trial by Sandell, Rolf et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1186/s13063-015-0656-7
Document Version
Early version, also known as pre-print
Link to publication record in King's Research Portal
Citation for published version (APA):
Sandell, R., Svensson, M., Nilsson, T., Johansson, H., Viborg, G., & Perrin, S. (2015). The Pose study - panic
control treatment versus panic-focused psychodynamic psychotherapy under randomized and self-selection
conditions: study protocol for a randomized controlled trial. Trials, 16, [130]. 10.1186/s13063-015-0656-7
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
Trials
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
The POSE study - panic control treatment versus panic-focused psychodynamic
psychotherapy under randomized and self-selection conditions: study protocol for a
randomized controlled trial
Trials Sample
doi:10.1186/s13063-015-0656-7
Rolf Sandell (rolf.sandell@psy.lu.se)
Martin Svensson (Martin.A.Svensson@regionhalland.se)
Thomas Nilsson (Thomas.K.Nilsson@skane.se)
Håkan Johansson (hakan.johansson@psy.lu.se)
Gardar Viborg (gardar.viborg@psy.lu.se)
Sean Perrin (sean.perrin@psy.lu.se)
Sample
 
ISSN 1745-6215
Article type Study protocol
Submission date 10 December 2014
Acceptance date 16 March 2015
Article URL http://dx.doi.org/10.1186/s13063-015-0656-7
 
 
For information about publishing your research in BioMed Central journals, go to
http://www.biomedcentral.com/info/authors/
 
© 2015 Sandell et al.; licensee BioMed Central.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
 (2015) 16:130 
The POSE study - panic control treatment versus 
panic-focused psychodynamic psychotherapy under 
randomized and self-selection conditions: study 
protocol for a randomized controlled trial 
Rolf Sandell1 
Email: rolf.sandell@psy.lu.se 
Martin Svensson1 
Email: Martin.A.Svensson@regionhalland.se 
Thomas Nilsson1 
Email: Thomas.K.Nilsson@skane.se 
Håkan Johansson1 
Email: hakan.johansson@psy.lu.se 
Gardar Viborg1 
Email: gardar.viborg@psy.lu.se 
Sean Perrin1*,2 
* Corresponding author 
Email: sean.perrin@psy.lu.se 
1 Department of Psychology, Lund University, Box 213, Lund 221 00, Sweden 
2 Institute of Psychiatry, Psychology and Neurosciences, Box PO77, King’s 
College London, 16 DeCrespigny Park, London SE5 8AF, UK 
Abstract 
Background 
Panic disorder with or without agoraphobia is a commonly occurring disorder affecting 2 to 
3% of the population in Sweden. Untreated, panic disorder is a chronic condition that 
significantly increases the risk for psychiatric comorbidity, morbidity and mortality, 
employment difficulties, and healthcare utilization. Cognitive behavioral approaches are the 
recommended first-line treatment for panic disorder; however, many patients in routine care 
receive another evidence-based psychotherapy, including psychodynamic therapy. Allowing 
patients to choose among evidence-based approaches to panic disorder may improve 
outcomes and reduce overall health costs. Trials comparing the ‘gold standard’ treatment for 
panic disorder to other evidence-based psychotherapies are needed, and also trials that can 
separate patient preferences for treatment from randomization effects on outcome, disability 
and healthcare utilization in the longer term. 
Methods/Design 
A phase 2/3 doubly-randomized controlled trial carried out in routine care with 216 adults 
(aged 18 to 70 years) with a primary diagnosis of DSM-IV Panic Disorder (with or without 
Agoraphobia). Within each clinic, patients are randomized to self-selection, random 
assignment of treatment, or wait-list. Patients choose or are randomly assigned to either Panic 
Control Treatment or Panic-Focused Psychodynamic Psychotherapy. Primary outcomes are 
changes in panic symptom severity, occupational status, and sickness-related absences from 
work at post-treatment and 6, 12 and 24 months post-treatment. Secondary outcomes include 
changes in agoraphobic avoidance, psychiatric comorbidity, disability, and healthcare 
utilization. The study also employs elements of an effectiveness trial as therapist and service-
related effects on outcome will be estimated. Putative change mechanisms for the two 
treatments are also assessed. 
Discussion 
Cognitive behavioral and psychodynamic therapies are both evidence-based approaches that 
are routinely offered to panic disordered patients in Sweden. However, little is known about 
the relative effectiveness of these two approaches for panic/agoraphobia, work-related 
disability and healthcare utilization over the longer term. The current trial (POSE) also 
addresses the important but understudied issue of whether patient preference for a particular 
psychotherapeutic approach moderates outcome. 
Trial registration 
ClinicalTrials.gov NCT01606592 (registered 19 March 2012). 
Keywords 
Randomized preference trial, Panic disorder, CBT, Psychodynamic therapy, Health 
economics 
Background 
Panic Disorder (PD) without Agoraphobia as defined in the 4th edition of the Diagnostic and 
Statistical Manual for Mental Disorders (DSM-IV) (American Psychological Association, 
2000) involves recurrent, unexpected panic attacks with at least one attack followed by 
persistent concerns or worries about additional attacks, and/or significant changes in behavior 
related to the attacks. PD with Agoraphobia involves the additional requirement that the 
individual avoids or endures with marked distress (often necessitating a companion to 
accompany them) places or situations from which it might be difficult (or embarrassing) to 
escape and/or to receive help in the event of a panic attack [1]. In DSM-V, the two disorders 
are de-linked so that individuals with both PD and Agoraphobia receive two diagnoses [2]. 
As this study commenced prior to the publication of DSM-V, we used the DSM-IV criteria 
with treatment focused on patients with a primary diagnosis of PD - with or without 
Agoraphobia. 
In accordance with prevalence studies carried out elsewhere [3,4], the 12-month prevalence 
of PD in Sweden is 2 to 3% and one of the most frequent causes of illness among Swedes 
aged 15 to 44 years [5]. When untreated, PD is a chronic and debilitating condition associated 
with an increased risk of psychiatric comorbidity, health complaints, low quality of life, 
diminished capacity for work, morbidity and mortality, a heavy burden on the family, and 
significantly increased healthcare utilization [5-10]. The presence of PD, especially with 
agoraphobia, is recognized as a major obstacle to Swedish adults returning to work after a 
period of sick leave and to young people attempting to enter the labor force for the first time 
(50% of whom with PD fail to do so) [5]. When last estimated (1996), the total cost of PD in 
Sweden was estimated at 1.7 billion euros per annum [5]. Effective treatment of PD has been 
shown to reduce the cost of care by as much as 94% [11]. 
Cognitive behavioral therapy (CBT) and pharmacotherapy are the recommended treatments 
for adults with PD in many countries [12-14] and the same is true in Sweden [5]. Numerous 
meta-analyses have been carried out and overall they find that both treatments, either alone or 
in combination, yield large effect sizes when compared with no/minimal treatment and 
medium effect sizes relative to psychological/drug placebo in the acute phases of treatment 
[15-17]. Effect sizes beyond 12 to 24 months are generally more modest than at post-
treatment or 6 month follow-up, particularly for (mono) pharmacotherapy, with little 
evidence of further symptomatic improvement during the follow-up period [14-18]. The use 
of pharmacotherapy alone is also associated with a significantly increased risk of attrition 
during treatment and relapse when treatment is discontinued [15,19]. Thus, there is an 
emerging consensus that CBT should be offered first to PD patients and to those 
discontinuing pharmacotherapy [5,14,15,17]. Whether another evidence-based psychotherapy 
could also be offered remains unclear, as there have been extremely few trials involving PD 
patients and comparisons between CBT and an active psychological treatment [20]. 
The longer-term efficacy of CBT for PD also remains unclear [17,21]. Across randomized 
controlled trials (RCTs) the median length of follow-up is 6 months with few trials reporting 
findings past 12 months. Also, few trials involve designs that permit continued comparison 
between treatments or between treatment and control groups during the follow-up period. 
Conclusions about longer-term efficacy are further confounded by significant attrition and 
treatment-seeking during the follow-up period. 
Durham et al. [21] carried out a 2- to 14-year follow-up of participants in 8 RCTs of CBT for 
anxiety, 4 of which focused on PD and the others on Generalized Anxiety and Post-
Traumatic Stress Disorders (PTSD). Of those initially treated with CBT for PD, only 40% 
achieved sustained recovery (defined as the absence of any anxiety disorder) without the 
benefit of additional treatment (any) during the follow-up period. Even with additional 
treatment, only 54% of those initially treated with CBT for PD achieved long-term recovery 
[21]. Across all of the RCTs, ‘recovered’ patients had significantly worse scores on all 
subscales of the Brief Symptom Inventory, with most suffering from mild symptoms that 
were slightly disabling and 20% falling just below threshold for diagnosis. More favorable 
findings can be found in a recent multi-center RCT by Gloster et al. [22] comparing 2 forms 
of CBT for PD as 74% of patients who were responders at post-treatment retained this status 
at 24 months. However, 37.5% of all CBT treated patients sought further treatment between 6 
and 24 months and this was unrelated to anxiety severity at 6 months. Further favorable 
findings are available from an earlier uncontrolled study of PD patients treated with CBT 
wherein 82% of initial treatment responders remained in remission at 5 or more years post-
treatment and 62% at 10 years or more [23]; however, the patients were less ill to begin with. 
It is important to note that most RCTs involving PD patients have focused primarily on 
changes in symptoms (panic, agoraphobia, and depression) and general indices (often 
clinician-rated) of overall impairment. Less is known about the impact of evidence-based 
approaches on the other aspects of disability that usually accompany PD such as absences 
from work due to sickness, difficulties returning to work and increased healthcare utilization 
[24]. Reducing symptoms per se does not necessarily improve these aspects of functioning 
[24-26]. There is some evidence that short-term therapies are less effective than longer 
therapies on improving return to work after sick leave in depressed and anxious patients 
[24,27]. However, the general move in health services overall is towards briefer, not longer, 
psychological treatments. 
What about attrition in CBT and pharmacotherapy? PD patients fear somatic symptoms and 
often the medical side effects that can accompany pharmacotherapy, and these fears may 
represent a major reason why PD patients often refuse medication when first offered (pre-
treatment attrition) or why as many as one third prematurely discontinue pharmacotherapy 
once begun [28,29]. Limited data is available about pre-treatment attrition in relation to CBT. 
In a study of 731 patients (22% with PD) presenting to a specialist anxiety service, all of 
whom were offered CBT outside of a clinical trial, the authors found that 30% dropped out 
before commencing CBT with 12.6% actively refusing CBT [30]. Although drop-out from 
CBT once begun was relatively low in the previous study (10.7%), a meta-analysis of RCTs 
by Haby et al. involving patients with either primary PD, Generalized Anxiety Disorder, or 
depression reported an average drop-out rate of 17% for PD patients treated with CBT (range 
= 0 to 54%) [18]. 
The dominance of CBT in the treatment of anxiety over the past two decades has meant that 
relatively few RCTs have been carried out comparing this approach to another active 
psychological treatment [31,32]. The majority of comparative psychotherapy trials for 
patients with PD have involved two forms of CBT (for example, cognitive versus behavioral, 
with/without therapist-guided exposure, self-help, Internet-based, and so on). Psychodynamic 
therapy (PDT) is an evidence-based treatment for a range of conditions involving a 
significant anxiety component [32,33]. While much fewer RCTs of PDT exist than for CBT, 
meta-analytic reviews have been carried out to estimate the effectiveness of PDT for a range 
of problems including anxiety [34-38]. In the 2 most recent [35,36], PDT was observed to be 
no less effective for anxiety than other active treatments in the short or long term, had similar 
drop-out rates (17%) as reported for CBT, and yielded controlled effect sizes relative to 
no/minimal treatment or treatment as usual in the medium range (g = 0.63). These effects 
were persistent at follow-ups of 6 to 12 months; however, the limited number of trials 
(focused primarily on social anxiety) and the significant heterogeneity between trials limits 
the conclusions that can be drawn [36]. Further comparative trials involving PDT and CBT 
are needed [13]. 
Milrod et al. [39] have developed a brief form of PDT titled Panic-Focused Psychodynamic 
Psychotherapy (PFPP). In an open trial of PFPP with 21 panic disordered patients (most with 
comorbid agoraphobia), 16 (76%) experienced a remission of their panic/agoraphobic 
symptoms at post-treatment with gains maintained at 6 months [40,41]. In a subsequent RCT 
involving 49 PD patients, those receiving PFPP were significantly more likely to have their 
panic symptoms remit at termination than patients receiving applied relaxation training (73% 
versus 39%) with PFPP gains (and differences between the groups) maintained at 12 months 
[42]. PFPP was well-tolerated with only 7% withdrawing prematurely as compared to 34% in 
the applied relaxation condition. More recently, Beutel et al. carried out a randomized 
controlled trial of PFPP and CBT (plus exposure) delivered in routine care to 54 patients with 
PD (the majority with agoraphobia) [43]. Remission rates at post-treatment were 44% for 
PFPP rising to 50% at 12-month follow-up compared to a 66% remission at post-treatment 
for CBT decreasing to 56% at follow-up. The differences between the two treatments were 
non-significant. 
While further comparative trials between PFPP and CBT for PD are clearly needed, Brewin 
and Bradley [44] have argued that RCTs comparing two or more treatments may give 
misleading results if patients’ preferences for the offered treatment alternatives are not 
controlled for. Thus, to the extent that patients’ preferences reflect their suitability for a 
specific type of psychotherapy, the one that is the most suitable for the majority of the patient 
population will appear superior, even if the treatments are equally effective. In a qualitative 
follow-up study of patients who had received CBT and PDT, patients who had unsuccessful 
treatment felt they had received a form of therapy that was less suitable to their individual 
needs and disposition and had well-developed ideas about how a more effective treatment 
should have been carried out [45]. A series of studies have shown that most people given 
adequate information will voice definite ideas about the kind of treatment that might be most 
suitable to their needs: so-called ‘helpfulness beliefs’ [46-48]. The resulting preferences are 
significantly moderated by the patient’s previous experiences with psychotherapy or 
psychiatry in general and generate a distribution of what may be a proxy for the ‘suitability 
differential’ between different forms of psychotherapy [48]. 
So, in a trial comparing two or more treatments where patients are allowed to select their 
preferred evidence-based treatment, one might reasonably predict little or no difference 
between the treatment groups. Also, if one assumes that outcome is at least partly moderated 
by the quality of the treatment alliance, one might reasonably expect stronger effects 
generally for treatments that were patient-selected than randomly assigned. It is possible to 
separate the effects of patient preference from the effects of randomization (that is treatment) 
by using a hybrid, double-randomization design [49]. In such a trial patients are randomized 
to self-selection or random assignment of treatment conditions. 
While patient preferences have drawn considerable attention as a potential moderator of 
treatment outcome [46-48,50,51], no such hybrid randomized controlled study (comparing 
treatment and preference effects) has yet been published for PD patients. A recent study by 
Watzke et al. [52] compared systematic treatment selection to randomized assignment of 
treatment, either non-protocol CBT or PDT, on outcomes for a wide range of disorders 
(including anxiety) in 291 inpatients. In the systematic treatment selection condition, the 
inpatient team arrived at a consensus decision about the most appropriate treatment based on 
diagnosis, psychometric assessment, capacity for self-reflection, and patient goals. The 
authors found no overall differences in outcome between patients in the randomized 
assignment and systematic treatment selection conditions. Patients who were systematically 
assigned to PDT had better long-term outcomes than patients who were randomly assigned to 
this same treatment but no such effects were found for CBT. 
The role of patient preference for a particular evidence-based approach is better illustrated in 
a recent hybrid RCT preference trial by Le et al. [53]. The investigators randomized 218 
patients with a primary diagnosis of PTSD to patient-preference or randomly-assigned 
treatment conditions involving either prolonged exposure therapy (a form of CBT) or 
sertraline. Overall, giving patients a choice over treatment yielded significantly lower health 
costs and more quality-adjusted life years (QALYs) than random assignment to treatment 
conditions. Interestingly, prolonged exposure therapy was less costly and yielded more 
QALYs relative to sertraline when the treatment was assigned rather than chosen. 
CBT and pharmacotherapy are currently the ‘gold standard’ treatments for PD. 
Pharmacotherapy will remain an important treatment option for many patients but pre- and 
post-treatment attrition for pharmacotherapy remains a significant concern. CBT is clearly an 
effective approach for PD but not for every patient and longer-term gains remain somewhat 
unclear. Also, the state of the literature is such that those advocating for the increased use of 
CBT in routine care for patients with PD will struggle to point to data showing its 
incremental effectiveness over other evidence-based psychotherapies that are also routinely 
provided in mental health services. Increasingly, both healthcare service providers and 
treatment guidelines have recommended that patients be encouraged and supported in 
choosing between various treatment options and being more active in the way treatment is 
delivered. It is possible that allowing patients to choose among evidence-based approaches 
may improve outcomes and reduce the overall burden and cost of illness. Further trials are 
needed involving comparisons between CBT and other evidence-based psychological 
approaches to help patients make better, data-informed choices about which treatment is 
likely to work best for them in the short and longer term. 
Study aims and objectives 
The primary aim of the project is to investigate the extent to which patient’s preferences for 
treatment influences a broad range of primary and secondary outcomes: panic symptom 
severity, agoraphobic avoidance, occupational status, sickness-related absences, subjective 
working ability, psychiatric comorbidity, panic and depression-related disability, and 
healthcare/medication utilization. A secondary aim is to compare outcomes for PCT, which is 
the form of CBT with the largest evidence base for PD, to PFPP, both of which are already 
delivered in routine care facilities in Sweden. A tertiary aim is to evaluate in a multivariate 
fashion, interactions between patient preference and other potential moderators of outcome 
(for example, gender, age, symptom severity, Axis I and II comorbidity, medication use, 
strength of the therapeutic alliance, and therapist effects). Finally we aim to evaluate putative 
mechanisms of change associated with each of the evaluated treatments (for example, 
cognitive and behavioral change, reflective capacity). 
Methods/Design 
Study design 
PCT and PFPP will be compared under two conditions, one in which patients are randomized 
to either form of therapy, and one in which they are asked to choose between them after 
having duly informed themselves about the two alternatives. The design is in keeping with 
recommendations for preference trials described by Long et al. [49]. 
Setting 
The study is carried out in ten outpatient mental health clinics located in three regions of 
Southern Sweden: Skåne (including Lund, Malmö, Eslöv, Arlöv and Trelleborg), Halland 
(including Halmstad, Falkenberg and Varberg), Jönköping (including Värnamo) and 
Dalecarlia (including Dalarna). These clinics are state-funded and responsible for the care 
and treatment of all individuals within their catchment area. The clinics receive referrals from 
the GP (family doctor), social services, employers, and directly from patients. In some cities 
some patients may be offered a brief psychological treatment in what are termed ‘first-line’ 
services (usually located in the GP clinics). However, and in the majority of cases, the clinics 
participating in this study are the first-line service for patients with mental health problems 
including panic and other anxiety disorders, and particularly those with significant psychiatric 
comorbidity or impairment in functioning. PCT and PFPP are delivered by therapists 
employed in the same clinics where the patient would ordinarily be treated. 
Participant inclusion criteria 
We aim to maximize the external validity of the study to the extent possible by making the 
inclusion criteria as least restrictive as possible. Inclusion criteria are the following: 
• Aged between 18 and 70 years 
• Current, principle diagnosis of DSM-IV PD with/without Agoraphobia and more 
specifically: 
• Have experienced at least 1 panic attack per week during the 3 weeks preceding the start of 
treatment; or 
• If PD with Agoraphobia is the principal diagnosis and the patients actively avoids 
situations that cause them panic, then the patient must: 
• Score ≥ 5 on an apprehension question about having a panic attack; or 
• Score ≥ 4 on the Avoidance-Alone Subscale of the Mobility Inventory for Agoraphobia; or 
• Meet DSM-IV PD criteria and not be more appropriately diagnosed as Agoraphobia 
without a history of PD; 
• Not currently engaged in on-going psychotherapy treatments and willing to refrain from 
starting non-study treatments during the treatment phase of the trial (discussed further 
below under screening and baseline assessment) 
• Medications, if used, must be held constant throughout the treatment phase of the study, 
and patients will only be accepted if they have been on a stable dose of standard anti-panic 
medication for at least 1 month and continue to meet criteria for a current diagnosis of PD 
with or without Agoraphobia; and 
• Ability to complete the active treatment phase (not including follow-ups) within 16 weeks 
Participant exclusion criteria 
• Current substance abuse/dependence. Patients with a prior history of substance 
abuse/dependence must have been in remission for this condition for at least 12 months 
prior to entering trial treatment; or 
• Current psychosis, delusions, or mania; or 
• Acutely suicidal; or 
• A history and current clinical presentation of at least one clinically-significant medical 
condition (for example, brain damage, degenerative neurological condition) sufficient to 
cause cognitive or physical impairments that might prevent full participation in treatments; 
or 
• Active involvement in a legal dispute related to their mental health 
Recruitment procedure 
This trial is carried out with significant support from regional health authorities and thus the 
primary means of recruitment is through state-funded, outpatient mental health clinics. 
Information about the study is posted in waiting rooms and all clinic staff are made aware of 
the study and asked to inform new referrals and existing patients who suffer from problems 
related to anxiety and panic specifically about the trial. Information about the trial is also 
available through a Project POSE website. Individuals with panic-related problems who visit 
the website are invited to contact the researchers for further information about the trial and an 
assessment of trial eligibility. Recruitment levels at the ten different sites are monitored on a 
monthly basis and problems addressed at the appropriate organizational level. Protocols 
governing inclusion have been developed and disseminated to facilitate a strict and coherent 
plan of action across sites, treatments conditions, therapists and site managers should 
problems arise. 
Screening and baseline assessment 
When a clinic identifies a potential participant, or when a participant directly contacts a 
member of the research team, an initial phone screening is carried out and the patient is 
informed about the trial, and inclusion and exclusion criteria are discussed. Patients who are 
currently receiving psychotherapy for PD or any other condition are strongly advised to 
complete their current course of treatment and then re-contact the team if they are still 
interested in participation. (At the time of writing, 138 patients have been enrolled in the trial. 
Of these, none were receiving ongoing psychotherapy for any condition at the time of 
screening. Only two patients who were receiving psychotherapy for PD expressed an interest 
in the trial and both were asked to complete their treatment before re-contacting the team and 
were not enrolled.) Patients who are currently receiving medication for anxiety or any other 
psychiatric condition are advised to meet with their psychiatrist and to bring a copy of the 
trial information form to discuss participation and the trial criteria regarding medication 
before agreeing to further assessment for the trial. 
Provided the patient has problems primarily of an anxious nature, wants treatment and does 
not meet any of the exclusion criteria, a face-to-face assessment is scheduled. Before this 
assessment the patient is provided with further information about the trial to read and a range 
of questionnaires to complete (described below). During the face-to-face assessment the 
patient undergoes a structured diagnostic interview with a member of the research team to 
establish that DSM-IV PD with or without Agoraphobia is the current and principal 
diagnosis, the Panic Disorder Severity Scale is administered, and lastly a structured 
diagnostic interview is carried out to assess DSM-IV Axis II Personality Disorders. If the 
patient has PD with or without Agoraphobia and no exclusion criteria are met, the patient 
gives written consent to participate and is then randomized. Patients who are excluded at any 
time during the baseline assessments are encouraged to contact their local GP and/or mental 
health clinic, and where requested/necessary a formal letter of referral is prepared by the trial 
assessor. 
Inclusion measure 
In keeping with the recommendations for standardized assessment of panic disordered 
patients described by Shear and Maser [54] and followed in most RCTs with panic disordered 
patients, inclusion is based on diagnostic status as assessed by the Structured Clinical 
Interview for DSM-IV (SCID-I) [55]. 
Primary outcome measures 
• Panic Disorder Severity Scale [56] 
• Panic Disorder Severity Scale-Self Report [57] 
• Occupational status 
• Patient report of the total of number of absences from work due to sickness (and 
compensation for the same as part of the secondary, healthcare utilization outcome) 
The above outcome measures are all assessed at baseline, post-treatment and 6-, 12- and 24-
month follow-ups. The total of number of absences from work due to sickness at baseline is 
measured as including the 3 months prior to commencing treatment. 
Secondary outcome measures 
• Psychiatric comorbidity as assessed by the Structured Clinical Interview for DSM-IV Axis 
I diagnoses [55] and Structured Clinical Interview for DSM-IV Axis II diagnoses [58] 
• Mobility Inventory for Agoraphobia [59] 
• Montgomery Åsberg Depression Rating Scale [60] 
• Sheehan Disability Scale [61] 
• Clinical Outcomes in Routine Evaluation [62] 
• Work Ability Index [63] 
• Number of absences from work due to sickness before, during and after treatment as 
recorded in the Longitudinal Integration Database for Health Insurance and Social Studies 
(LISA) that is maintained by the Swedish Central Statistical Office 
• Patient report of healthcare utilization (for example, number of medical contacts, 
emergency room visits, prescription medication use) 
• Use of psychotropic medication as recorded by the Swedish National Board of Health and 
Welfare register of consumption of psychotropic drugs; and 
• Estimation of the total expected costs of each treatment alternative against the total 
expected benefits 
Randomization and allocation concealment 
Randomization is done sequentially as patients are included in study. At the level of the 
clinic, there must be at least one PFPP and one PCT therapist working in the trial. The 
randomization procedure was designed to ensure equal numbers of patients in each condition 
at clinic level. 
Because of the length of the follow-up (24 months) and the heavy assessment burden for 
patients throughout the trial, there is an increased risk of attrition during the follow-up period. 
To help minimize this risk, an effort is made to establish a good working relationship 
between a single trial assessor (who is not involved in delivering treatment) and each patient 
and to have the same assessor carry out the baseline, post-treatment and 6-, 12- and 24-month 
follow-up assessments. Because the baseline assessor reveals the randomization results to the 
patient, the post-treatment and follow-up interviews are not carried out blind to treatment 
condition. However all post-treatment and follow-up interviews are recorded and these 
interviews will be evaluated by independent raters who are blinded to treatment condition and 
these ratings will be reported. 
Treatment protocol 
PCT is a manualized, individual cognitive behavioral treatment for adults with PD (with or 
without agoraphobia) [64]. Patients are helped to become panic-free by learning to anticipate 
and respond to situations that trigger their panic attacks and to manage the physical 
symptoms of panic using techniques such as controlled breathing. PCT ordinarily consists of 
12 weekly therapy sessions. In the current trial, PCT involves 12 to 14 sessions completed 
within 10 to 16 weeks; week 1 includes 2 sessions and subsequent weeks 1 session each. 
Between 2 and 5 sessions will include therapist-assisted exposure. Each session is 60 minutes 
in duration, extended to 90 to 120 minutes for those including therapist-assisted exposure. 
Total treatment duration will be 780 to 1,140 minutes. 
Session 1 of PCT involves psycho-education about the nature of PD and agoraphobia. In 
Session 2 the patient learns the importance of (and how to) recording their daily levels of 
anxiety/panic so that they can monitor progress alongside their therapist. Sessions 3 to 12 
involve cognitive restructuring of anxiety-related cognitions and structured, therapist-guided 
exposure to situational/somatic cues that may be associated with panic attacks and 
agoraphobic avoidance. A single session teaches clients how to slow their breathing rate to 
counter the effects of hyperventilation. 
PFPP is a manualized, individual psychodynamic treatment for adults with PD (with or 
without agoraphobia) [38]. Treatment is ordinarily 19 to 24 sessions in length with 2 sessions 
per week, 45 minutes each. PFPP delivered in the current trial comprises 19 to 24 sessions 
completed within 10 to 16 weeks; in principle 2 sessions per week, 45 minutes each. Total 
treatment duration will be 855 to 1,080 minutes. 
PFPP proceeds in three phases. In Phase I the therapist works to identify the specific content 
and meanings of the panic episodes and to help the patient examine the stressors and feelings 
surrounding the onset and persistence of panic. Specific vulnerabilities to the development of 
panic from the patient’s past are explored (for example, representations of parents, traumatic 
experiences, difficulty expressing and managing angry feelings). The patient is aided in 
bringing forth fantasies and feelings that may have been unconscious or difficult to tolerate, 
such as vengeful wishes or abandonment fears, and to identify intra-psychic conflicts 
surrounding anger, separation, and sexuality. The goal of this phase is reduction in panic 
symptoms. 
Phase II seeks to address the dynamics that maintain vulnerability to panic and the 
persistence of panic symptoms (for example, difficulties with anger recognition and 
management, separation, and fears of loss or abandonment). These dynamics are addressed 
through discussion of the patient’s feelings/fantasies about past/present relationships and in 
the transference relationship with the therapist. Improved understanding of these conflicts 
helps to prevent the development of a vicious cycle of PD recurrence. 
In Phase III the therapist and patient work with the patient’s conflicts with anger and 
separation as they emerge in the context of termination. Increased assertiveness and the 
capacity to communicate about conflicts in relationships should improve quality of life and 
reduces panic vulnerability. Thus the patient is helped to experience and articulate their 
feelings about loss and anger directly with the therapist to facilitate better management of 
these feelings and the capacity to avert the development of more severe panic states. 
Treatment integrity 
Treatment integrity refers to the degree to which an intervention is delivered as intended. 
Therapists in the trial provide only one form of treatment during the study and the vast 
majority will provide only CBT or only PDT as part of their usual practice. Treatment 
integrity encompasses three aspects: a) therapist treatment adherence (the degree to which the 
therapist utilizes prescribed procedures and avoids proscribed procedures); b) therapist 
competence (the level of the therapist’s skill and judgment); and c) treatment differentiation 
(whether competing treatments differ from each other along critical dimensions). 
All three aspects of treatment integrity are addressed throughout the trial in keeping with the 
standards for the field proposed by Perepletchikova et al. [65]. The first two aspects are 
addressed firstly through training and supervision of trial therapists in PCT and PFPP prior to 
their participation in the study. Prior to commencement of patient recruitment therapists and 
supervisors receive workshops in PCT and PFPP and additional workshops are arranged each 
year of the trial. Therapists must also treat as per-protocol (videotaping sessions) a ‘training’ 
case under supervision from a trial-trained supervisor. Videotapes from this therapy are 
evaluated by another experienced supervisor of PCT or PFPP for treatment adherence. 
During the trial therapists continue to videotape treatment sessions and to receive 
supervisions from a trial-trained supervisor. The supervisor rates therapist adherence during 
supervision and provides feedback to the therapist about the same. Adherence is also 
controlled for each patient therapy by three ratings (beginning, middle and end of therapy) 
made by independent raters with feedback from these ratings given to trial supervisors to use 
with therapists. A minimum of three site visits per annum from the research team are 
scheduled to ensure (improve) site protocol adherence. 
Project implementation plan 
Point prevalence of PD in the Swedish general population is 2 to 3% [5], which means that 
over 40,000 individuals currently have PD in the regions of Halland, Skåne and Dalecarlia. 
Given an inclusion period of 6 years (2011 to 2016) about 40 patients have to be recruited 
each year. Trial therapists are expected to treat about three patients each per year. The study 
is carried out at 10 sites in the counties of Skåne (Lund, Malmö, Eslöv, Arlöv and 
Trelleborg), Halland (Halmstad, Falkenberg and Varberg), Jönköping (Värnamo) and 
Dalecarlia. All participating therapists work in primary healthcare centers or psychiatric 
outpatient clinics. Currently, 35 therapists are active in the project. All clinics have signed 
written agreements to supply the project with patients during the inclusion phase. Intake and 
treatment of patients began in 2011. This phase is scheduled to last 5 years until 2016. 
Follow-up studies will be completed in 2018. 
Power/sample size calculations 
For the planned and relatively straightforward comparisons between the 2 active treatments 
(PCT and PFPP) and wait-list, 25 patients per group would be needed in order to ensure an 
effect size (Cohen’s d) of 0.8 at alpha = 0.05 and power = 0.80. Our assumption of an effect 
size difference versus wait-list of d = 0.8 is conservative relative to the average controlled 
effect size (d = 1.02, 95% CI = 0.86 to 1.18) reported in a recent meta-analysis of 61 RCTs 
comparing psychological treatments for PD to no treatment or psychological/drug placebo 
[17]. For the planned and straightforward comparison between the randomized and self-
selection conditions, we have assumed that the difference between the two conditions will be 
in the order of d = 0.4. Again our assumption is conservative relative to the average effect 
size obtained for self-selection versus randomization in preference trials involving treatments 
for anxiety (d = 0.49, 95% CI = 0.19 to 0.79), albeit based on a much smaller number of 
RCTs [66]. For the more complex comparisons involving the hypothesized interaction 
between assignment type (randomization or self-selection) and treatment type (PCT or 
PFPP), power calculations have been performed based on the PINT (Power IN Two-level 
designs, v. 2.12, September 2007) [67,68]. In the absence of a priori information about the 
size of the interaction effect between assignment and these 2 specific treatments, we assume 
the interaction effect size will be comparable in size to the main effect size for assignment 
(that is d = 0.40). At alpha = 0.05, power = 0.80 and d = 0.4, a total of 200 patients is 
required. Assuming a 15% drop-out rate, a total of 212 patients is required. 
After consideration of issues pertaining to practicality of randomization, the target 
recruitment is N = 216. This was based on the following tentative assumptions, among others: 
Assignment (randomized versus self-selected) is a fixed effect on Level 1 with M = 0 and SD 
= 1; the Pre-treatment measure is a random and fixed effect on Level 1; Treatment (PCT 
versus PFPP) is a Level 2 predictor with M = 0.0625 (given a 55:45 distribution in the self-
selection group) and SD = 1; residual variance in post-treatment = 0.70; and explained 
variance on outcome across therapists = 0.05. 
The 216 patients will be randomly allocated to the randomized condition, the self-selection 
condition or to the waiting-list in the following shares: 108: 108: 26 (See Figure 1 for 
Consolidated Standards of Reporting Trials (CONSORT) flow chart). After 3 months patients 
on the waiting-list will be re-randomized to randomization or to self-selection. The self-
selection condition allows the patient to choose either PFPP or PCT. The actual choice is 
made after reading a detailed and well-balanced presentation of the two alternative therapies. 
These presentations have been developed and tested in an unpublished study by Hultman. 
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) flow chart. 
Ethical considerations 
Ethical approval was obtained from the Regional Ethical Review Board in Lund (Ref: DNR-
2010/88). Ethical and professional guidelines will be followed at all times, in line with Good 
Clinical Practice guidelines, and the laws governing patient care and data protection in 
Sweden. Informed consent is obtained from every participant in the trial. Any potential 
adverse events are discussed with the treating therapist, their clinical supervisor (and 
employer as necessary), and the research team (including the relevant university 
representative), and any identified adverse events are recorded. Adverse events are reported 
to the trial funder and will be reported as part of the trial findings. 
Discussion 
The ability of patients to choose freely among treatments in matters of health is stipulated by 
law in Sweden but choice is often sacrificed in the name of cost-effectiveness. However, 
policy-makers would do well not to limit patient choice to the most cost-effective treatment 
based on often limited evidence, when an alternative evidence-based approach that is not 
more expensive than the most cost-effective therapy is available, but is as yet understudied. 
Allowing patients to choose among evidence-based approaches will increase patient 
involvement and may result in improved patient safety and patient satisfaction. Likewise, 
providing patients access to their preferred (evidence-based) treatment is likely to increase 
compliance rates, thereby improving outcomes and reducing the overall cost and burden of 
illness [69]. 
Currently, CBT is the indicated first-line treatment for adult patients with PD in Sweden but 
healthcare authorities recognize that other evidence-based approaches that are understudied 
may also be effective [5]. Swedish mental health services benefit from the presence in routine 
care of psychotherapists with post-graduate (certified) training in a range of evidence-based 
approaches, primarily CBT, PDT and family therapy. However, comparative trials of these 
various approaches to PD have not been carried out in Sweden. The current trial will be the 
first randomized controlled trial in Sweden to compare CBT (PCT) to brief psychodynamic 
therapy (PFPP) delivered in routine care to patients with PD. The trial is also important in the 
emphasis placed on measuring the impact of treatment on work-related disability and 
healthcare utilization, both of which are significant costs associated with PD in Sweden and 
elsewhere. 
This project has the unique ambition to separate the effects of patients’ preferences for 
treatment from the effect of the different evidence-based psychotherapies under study. If a 
certain form of psychotherapy proves to be significantly more popular in the self-selection 
group, this is an interesting research finding in and of itself, which may ultimately have 
implications for how healthcare resources are allocated in Sweden and for the design of 
future comparative trials. Should PFPP prove to be as effective as the established ‘gold-
standard’ treatment for PD (CBT), the current trial will significantly add to the literature and 
the evidence base in favor of offering PD patients further choices among evidence-based 
treatments. 
Trial status 
Recruitment began in November 2011 and is ongoing. Slightly more than half of the target 
sample has been recruited (N = 138). 
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